News for Healthier Living
i-Lumen Scientific Announces First U.S. Patient Randomized in i-SIGHT2 Pivotal Study Evaluating Noninvasive Bioelectric Therapy for Intermediate to Advanced Dry AMD
i-Lumen Scientific, Inc., a clinical-stage medical technology company developing bioelectric therapies for retinal disease, today announced the first U.S. patient has been randomized in the i-SIGHT2 pivotal study evaluating the i-Lumen AMD System in patients with intermediate to advanced dry age-related macular degeneration (AMD).
July 21, 2026
July 25 2026July 24 2026July 23 2026July 22 2026July 21 2026July 20 2026July 17 2026July 16 2026July 15 2026July 14 2026July 13 2026July 12 2026
|
|
|
|
|